Skip to content
lifestyle.duovoltart.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
IGC Pharma, Inc.
Ascendiant Capital Markets Raises IGC Pharma Price Target to $5.50, Citing Clinical Progress and 2026 Catalysts
June 9, 2026
IGC Pharma Adds Mount Sinai Clinical Site as CALMA Trial Advances Toward Completion and Topline Analysis
June 2, 2026
IGC Pharma to Participate in Fireside Chat With Ascendiant Capital Markets
February 17, 2026
IGC Pharma Expands Phase 2 CALMA Trial with New Clinical Trial Site at Integrative Clinical Trials in New York
January 30, 2026
IGC Pharma Aligns Fiscal Year with Calendar Year to Enhance U.S. Investor Transparency and Comparability
January 9, 2026
←
Previous Page
1
2